Corcept Therapeutics, Inc. (NASDAQ:CORT)
CAPS Rating:
A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.
Growing the love for investing
A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
March 27, 2008 12:44 PM EDT
Corcept Therapeutics Inc. (Nasdaq: CORT) Director, Joseph Cook, bought 176,522 on 3/25 at $2.77, bringing his stake to 1,656,360 shares. In addition, Director, David Mahoney, bought 70,609 shares on 3/25 at $2.77, bringing his stake to 636,547 shares.
Corcept Therapeutics Incorporated develops drugs for the treatment of severe psychiatric and metabolic diseases. [LJ]